Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

<p><strong>Background</strong> COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before vaccination with the ChAdOx-nCoV19 (AZD1222) vaccine on antibody responses through...

Full description

Bibliographic Details
Main Authors: Madhi, SA, Kwatra, G, Richardson, SI, Koen, AL, Baillie, V, Cutland, CL, Fairlie, L, Padayachee, SD, Dheda, K, Barnabas, SL, Bhorat, QE, Briner, C, Ahmed, K, Aley, PK, Bhikha, S, Bhorat, AE, Esmail, A, Horne, E, Kaldine, H, Mukendi, CK, Madzorera, VS, Manamela, NP, Masilela, M, Hermanus, ST, Motlou, T, Mzindle, N, Oelofse, S, Patel, F, Rhead, S, Rossouw, L, Taoushanis, C, van Eck, S, Lambe, T, Gilbert, SC, Pollard, AJ, Moore, PL, Izu, A
Format: Journal article
Language:English
Published: Elsevier 2022

Similar Items